Clinical Observation of Fludarabine-based Chemotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma Patients

Objective To determine the efficacy and the safety of fludarabine-based chemotherapy for relapsed or refractory non-Hodgkin lymphoma patients. Methods Thirty-eight patients with relapsed or refractory non-Hodgkin lymphoma received FND regimen (fludarabine 30mg/m²iv. d1~3, mitoxantrone 10mg/m²iv. d1, triamcinolone 80mg PO d1~5, every 28 days). Results The overall response rates of all patients were 56%,CR 21%andPR 34%, respectively. Twenty patients were indolent lymphoma.Sevenpatients achieved CR and 9 patients achieved PR.The overall response rate was80%.Eighteenpatients were aggressive lymphoma. Onepatient achieved CR and 4 patients achieved PR.The overall response rate was 28%( P ＜0.05). The median PFS and OS of indolent lymphoma was 18(2~34) and45months, respectively. The median PFS and OSof aggressive lymphoma was 3(1~22) and15months, respectively. Myelosuppression and infection were the most common toxicities. Conclusion Fludarabine-based regimen is effective for indolent lymphoma patients and added an option for aggressive lymphoma patients.And drug-related toxicities are tolerable.